Atacicept, a Vera Therapeutics drug in development for the rare kidney disease immunoglobulin A nephropathy, is on its way to a pivotal test after achieving the main goal of a mid-stage clinical trial. But the results still fall short of data recently reported by a competitor that is addressing the same disease target.
Vera Therapeutics raised $47.9 million from its IPO to continue clinical development of its lead asset, a potential treatment for the kidney disease IgA nephropathy. But the company is joining a crowded field of companies aiming to develop a drug for the rare disorder.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Vera Therapeutics licensed the drug candidate after analysis of earlier trials revealed its promise. Boosted by $80 million in Series C funding, the company hopes to launch a phase 2B trial this year.